Reversible liver toxicity with adjuvant trastuzumab for localized breast cancer

被引：6
作者：
Munoz, A. [1 ]
Carrera, S. [1 ]
Ferreiro, J. [1 ]
de Lobera, A. Ruiz [1 ]
Mane, J. M. [1 ]
Lopez-Vivanco, G. [1 ]
机构：
[1] Osakidetza SVS, Hosp Cruces, Dept Med Oncol, Bizkaia 48903, Basque Country, Spain
来源：
ANNALS OF ONCOLOGY | 2007年 / 18卷 / 12期
关键词：
D O I：
10.1093/annonc/mdm515
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2045 / 2046
页数：2
相关论文
共 6 条
  • [1] Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
    Cobleigh, MA
    Vogel, CL
    Tripathy, D
    Robert, NJ
    Scholl, S
    Fehrenbacher, L
    Wolter, JM
    Paton, V
    Shak, S
    Lieberman, G
    Slamon, DJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) : 2639 - 2648
  • [2] Mackey JR, 2006, BREAST CANCER RES TR, V100, pS5
  • [3] Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    Piccart-Gebhart, MJ
    Procter, M
    Leyland-Jones, B
    Goldhirsch, A
    Untch, M
    Smith, I
    Gianni, L
    Baselga, J
    Bell, R
    Jackisch, C
    Cameron, D
    Dowsett, M
    Barrios, CH
    Steger, G
    Huang, CS
    Andersson, M
    Inbar, M
    Lichinitser, M
    Láng, I
    Nitz, U
    Iwata, H
    Thomssen, C
    Lohrisch, C
    Suter, TM
    Ruschoff, J
    Süto, T
    Greatorex, V
    Ward, C
    Straehle, C
    McFadden, E
    Dolci, MS
    Gelber, RD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) : 1659 - 1672
  • [4] Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Romond, EH
    Perez, EA
    Bryant, J
    Suman, VJ
    Geyer, CE
    Davidson, NE
    Tan-Chiu, E
    Martino, S
    Paik, S
    Kaufman, PA
    Swain, SM
    Pisansky, TM
    Fehrenbacher, L
    Kutteh, LA
    Vogel, VG
    Visscher, DW
    Yothers, G
    Jenkins, RB
    Brown, AM
    Dakhil, SR
    Mamounas, EP
    Lingle, WL
    Klein, PM
    Ingle, JN
    Wolmark, N
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) : 1673 - 1684
  • [5] Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
    Slamon, DJ
    Leyland-Jones, B
    Shak, S
    Fuchs, H
    Paton, V
    Bajamonde, A
    Fleming, T
    Eiermann, W
    Wolter, J
    Pegram, M
    Baselga, J
    Norton, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) : 783 - 792
  • [6] Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719
1